1 / 1

PCSK9 Monoclonal Antibody Impact on LDL-C in FH Patients: Regimen Comparison Study

This study investigates the effects of monoclonal antibody to PCSK9 on LDL-C levels in familial hypercholesterolemia patients. The study compares the efficacy of placebo and different dosages of REGN727 over 20 weeks, showing mean changes in LDL-C levels at various time points. Results were published in the Lancet in May 2012 by Stein EA, Gipe D, et al.

bianca-sellers
Download Presentation

PCSK9 Monoclonal Antibody Impact on LDL-C in FH Patients: Regimen Comparison Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Effect of monoclonal antibody to PCSK9 on LDL-C in FH patients Every 2 weeks Placebo REGN727 150 mg Every 4 weeks REGN727 200 mg REGN727 150 mg REGN727 300 mg Meanchange (%) Baseline Week 2 Week 4 Week 6 Week 8 Week 10 Week 12 Week 16 Week 20 LOCF Stein EA, Gipe D, et al., Lancet. 2012 May 25

More Related